IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine

In the last 20 years, dendritic cells (DCs) have been largely used as a platform for therapeutic vaccination in cancer patients. However, despite its proven safety and ability to induce cancer specific immune responses, the clinical benefits of DC-based immunotherapy are currently very limited. Thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Mookerjee, Ananda, Graciotti, Michele, Kandalaft, Lana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356194/
https://www.ncbi.nlm.nih.gov/pubmed/30621204
http://dx.doi.org/10.3390/cancers11010040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356194/
https://www.ncbi.nlm.nih.gov/pubmed/30621204
http://dx.doi.org/10.3390/cancers11010040

Ejemplares similares